Salix Pharmaceuticals (NASDAQ: SLXP ) reported good news from a phase 3 trial of Xifaxan in patients with irritable bowel syndrome with diarrhea (IBS-D), an additional potential indication for a drug that turned in nearly $650 million in sales last year.
Good news is nice, and given that analysts are estimating over $1 billion in annual peak sales for Xifaxan based on label expansions, it's nice to see good data coming through.
But is the stock a good investment? In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.
Leaked: This coming blockbuster will make even Salix jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.